Dr Reddy’s rises upon divesting two of its non-core anti-bacterial brands

Dr Reddy’s rises upon divesting two of its non-core anti-bacterial brands

by 5paisa Research Team Last Updated: Dec 15, 2022 - 12:06 am 36.5k Views
Listen icon

With this divestment, the company aims to consolidate and strengthen its position by focusing its resources and capabilities on its key therapy spaces.

Dr Reddy’s Laboratories Limited, a leading multinational pharmaceutical company has inked an agreement with Binnopharm Group for the acquisition of two anti-bacterial brands from Dr Reddy’s in the Russia and CIS region.

To ensure availability in the market, Dr Reddy’s will continue to supply the product to Binnopharm Group during the transition period.

The latter is one of the leading pharmaceutical production companies in Russia. It acquired anti-bacterial medicines under the Ciprolet and Levolet brands through its affiliate joint-stock company, Alium. Both the brands comprise various dosage forms such as tablets, solutions for infusions and eye drops. With this acquisition, Binnopharm Group intends to strengthen its antibiotic portfolio.

Why this divestment?

Dr Reddy’s operates in multiple therapeutic areas, with the key spaces being gastrointestinal, oncology, cardiovascular, pain management, respiratory, neurology, paediatrics and women’s health.

Both Ciprolet and Levolet brands fall under Dr Reddy’s non-core areas. With this divestment, the company aims to consolidate and strengthen its position by focusing its resources and capabilities on its key therapy spaces as the Russia and CIS region continues to be its strong performing markets.

Earlier this month, the company had entered into an exclusive sales and distribution agreement with Novartis India Limited for select Indian brands.

Looking at the performance in Q3FY22, on a consolidated basis, Dr Reddy’s net revenue went up by 8.33% YoY to Rs 5103.10 crore. PBIDT (ex OI) 125.42% YoY to Rs 1215.70 crore, whereas the corresponding margin expanded by 1186 bps YoY to 22.77%. The PAT increased by a stellar 5297% YoY to Rs 690.80 crore. The PAT margin expanded by 1268 bps YoY to 12.94%.

At noon, the share price of Dr Reddy’s Laboratories Limited was trading at Rs 4354.45, an increase of 0.77% from the previous week’s closing price of Rs 4321 on BSE.

Share Market Today


How do you rate this article?

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

378X91-D3

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Enjoy 0%* Brokerage with 5paisa
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest News
Teerth Gopicon IPO Debut with 12.6% Premium Opening at ₹125, Setting a Positive Tone

Teerth Gopicon IPO were floated for ₹125 on the NSE SME platform on April 16, representing a 12.6% premium over the issue price of ₹111.Gains were broadly consistent with the gray market, where the share was trading at ₹127 before of the IPO. The term "grey market" refers to unofficial, over-the-counter trading in securities before they are listed on exchanges.

Jefferies' Prediction for Bharati Hexacom: 'Double Your Money in a Year'

Jefferies is bullish on Bharti Hexacom, a Bharti Airtel group company, citing its strong growth prospects and healthy margin expansion.

Jio Financial Services Up 5% After BlackRock Joint Venture Announcement

Jio Financial Services Ltd witnessed a sharp rise in today's trading session following its announcement of a collaboration with BlackRock, a non-banking financial company (NBFC). The stock surged by 4.90 percent, reaching a day high of ₹371.75.